Conventional baculovirus vectors that utilize the very late polyhedrin promoter have not proved successful for expressing a thyrotropin (TSH) receptor capable of ligand and Graves' disease autoantibody binding comparable to the receptor produced in mammalian cells. Because of the clinical importance of high level expression of this protein, we reassessed the baculovirus system using a new transfer vector (pAcMP3) containing the late basic protein promoter, which functions earlier than the classical polyhedrin promoter. Maximal synthesis of the [S]methionine-labeled TSH receptor extracellular domain, affinity-purified using a 6-histidine tag, occurred earlier (1 day after insect cell infection) than with a vector (pVL1393) containing the polyhedrin promoter. The pAcMP3-derived TSH receptor extracellular domain was larger (68 kDa) than the pVL1393-derived protein (63 kDa). Only the 68-kDa product was secreted, albeit in trace amounts detectable only by precursor labeling. Enzymatic deglycosylation reduced both 68- and 63-kDa cellular proteins to 54 kDa, indicating that the pAcMP3 vector generated a protein with greater carbohydrate content. However, despite its greater degree of glycosylation, most of the 68-kDa protein remained within the cell, almost entirely in the particulate fraction. Remarkably, the trace amounts of 68-kDa receptor protein affinity-purified from the soluble cytosolic fraction of infected insect cells completely neutralized TSH receptor autoantibodies in patients' sera and partly inhibited TSH binding.

In conclusion, a baculovirus vector with a promoter active earlier than the conventional polyhedrin promoter generates a more glycosylated and functional TSH receptor extracellular domain protein, albeit at low levels. These data carry important implications for the expression by baculovirus vectors of functional, highly glycosylated proteins.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				B. S. Prabhakar, R. S. Bahn, and T. J. Smith Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy Endocr. Rev., December 1, 2003; 24(6): 802 - 835. [Abstract] [Full Text] [PDF]

				M. W. Szkudlinski, V. Fremont, C. Ronin, and B. D. Weintraub Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Structure-Function Relationships Physiol Rev, April 1, 2002; 82(2): 473 - 502. [Abstract] [Full Text] [PDF]

				J. G. Cundiff, S. Kaithamana, G. S. Seetharamaiah, J. R. Baker Jr., and B. S. Prabhakar Studies Using Recombinant Fragments of Human TSH Receptor Reveal Apparent Diversity in the Binding Specificities of Antibodies That Block TSH Binding to Its Receptor or Stimulate Thyroid Hormone Production J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4254 - 4260. [Abstract] [Full Text] [PDF]

				S. Kaithamana, J. Fan, Y. Osuga, S.-G. Liang, and B. S. Prabhakar Induction of Experimental Autoimmune Graves' Disease in BALB/c Mice J. Immunol., November 1, 1999; 163(9): 5157 - 5164. [Abstract] [Full Text] [PDF]

				M. H. Lee, J. Y. Park, B. Y. Cho, and C.-B. Chae Expression of the Functional Extracellular Domain of Human Thyrotropin Receptor Using a Vaccinia Virus System: Its Purification and Analysis of Autoantibody Binding J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1391 - 1397. [Abstract] [Full Text]

				B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text]

				C. R. Da Costa and A. P. Johnstone Production of the Thyrotrophin Receptor Extracellular Domain as a Glycosylphosphatidylinositol-anchored Membrane Protein and Its Interaction with Thyrotrophin and Autoantibodies J. Biol. Chem., May 8, 1998; 273(19): 11874 - 11880. [Abstract] [Full Text] [PDF]

				J. Guo, S. M. McLachlan, S. Hutchison, and B. Rapoport The Greater Glycan Content of Recombinant Human Thyroid Peroxidase of Mammalian Than of Insect Cell Origin Facilitates Purification to Homogeneity of Enzymatically Protein Remaining Soluble at High Concentration Endocrinology, March 1, 1998; 139(3): 999 - 1005. [Abstract] [Full Text] [PDF]

				Y. Osuga, S.-G. Liang, J. S. Dallas, C. Wang, and A. J. W. Hsueh Soluble Ecto-Domain Mutant of Thyrotropin (TSH) Receptor Incapable of Binding TSH Neutralizes the Action of Thyroid-Stimulating Antibodies from Graves' Patients Endocrinology, February 1, 1998; 139(2): 671 - 676. [Abstract] [Full Text] [PDF]

				S. Costagliola, P. Rodien, M.-C. Many, M. Ludgate, and G. Vassart Genetic Immunization Against the Human Thyrotropin Receptor Causes Thyroiditis and Allows Production of Monoclonal Antibodies Recognizing the Native Receptor J. Immunol., February 1, 1998; 160(3): 1458 - 1465. [Abstract] [Full Text] [PDF]

				J. Krieg, W. Glasner, A. Vicentini, M.-A. Doucey, A. Loffler, D. Hess, and J. Hofsteenge C-Mannosylation of Human RNase 2 Is an Intracellular Process Performed by a Variety of Cultured Cells J. Biol. Chem., October 17, 1997; 272(42): 26687 - 26692. [Abstract] [Full Text] [PDF]

				M. Grossmann, B. D. Weintraub, and M. W. Szkudlinski Novel Insights into the Molecular Mechanisms of Human Thyrotropin Action: Structural, Physiological, and Therapeutic Implications for the Glycoprotein Hormone Family Endocr. Rev., August 1, 1997; 18(4): 476 - 501. [Abstract] [Full Text] [PDF]

				G. D. Chazenbalk, J. C. Jaume, S. M. McLachlan, and B. Rapoport Engineering the Human Thyrotropin Receptor Ectodomain from a Non-secreted Form to a Secreted, Highly Immunoreactive Glycoprotein That Neutralizes Autoantibodies in Graves' Patients' Sera J. Biol. Chem., July 25, 1997; 272(30): 18959 - 18965. [Abstract] [Full Text] [PDF]

				H. Vlase, N. Matsuoka, P. N. Graves, R. P. Magnusson, and T. F. Davies Folding-Dependent Binding of Thyrotropin (TSH) and TSH Receptor Autoantibodies to the Murine TSH Receptor Ectodomain Endocrinology, April 1, 1997; 138(4): 1658 - 1666. [Abstract] [Full Text] [PDF]

				J. Y. Park, I. J. Kim, M. H. Lee, J. K. Seo, P. G. Suh, B. Y. Cho, S. H. Ryu, and C.-B. Chae Identification of the Peptides That Inhibit the Stimulation of Thyrotropin Receptor by Graves' Immunoglobulin G from Peptide Libraries Endocrinology, February 1, 1997; 138(2): 617 - 626. [Abstract] [Full Text] [PDF]

				M. Grossmann, R. Wong, N. G. Teh, J. E. Tropea, J. East-Palmer, B. D. Weintraub, and M. W. Szkudlinski Expression of Biologically Active Human Thyrotropin (hTSH) in a Baculovirus System: Effect of Insect Cell Glycosylation on hTSH Activity in Vitro and in Vivo Endocrinology, January 1, 1997; 138(1): 92 - 100. [Abstract] [Full Text] [PDF]

				Y. Nagayama, K. Tanaka, T. Hara, H. Namba, S. Yamashita, K. Taniyama, and M. Niwa Involvement of G Protein-coupled Receptor Kinase 5 in Homologous Desensitization of the Thyrotropin Receptor J. Biol. Chem., April 26, 1996; 271(17): 10143 - 10148. [Abstract] [Full Text] [PDF]

				A. Schmidt, R. MacColl, B. Lindau-Shepard, D. R. Buckler, and J. A. Dias Hormone-induced Conformational Change of the Purified Soluble Hormone Binding Domain of Follitropin Receptor Complexed with Single Chain Follitropin J. Biol. Chem., June 22, 2001; 276(26): 23373 - 23381. [Abstract] [Full Text] [PDF]